Article

Improving Quality-of-Life in Head and Neck Cancer Treatment

Patients with head and neck carcinoma were more likely to have a better quality-of-life if they had transoral robotic surgery.

Findings from a recent study suggest that quality-of-life for patients with squamous cell carcinoma of the head and neck can be affected by the treatment they receive.

In a study published by Plastic and Aesthetic Research, investigators included 45 studies that rated the patients’ health-related quality-of-life (HRQOL) after receiving various treatments. Researchers believe their findings could be used as a tool to individualize treatments for certain patients.

Treatments such as microvascular reconstruction, transoral robotic surgery, and adjuvant therapy with chemotherapy and radiation, are common treatments for squamous cell carcinoma of the head and neck. Patients with this type of cancer are likely to face side effects from the treatments, such as trouble swallowing, airway obstruction, speech problems, infections, fistulae, aspiration, and the need for permanent tracheostomy, according to the study.

HRQOL is typically measured in terms of side effects from the treatment, such as pain and appearance, among other things. In the study, researchers discovered that taste is commonly affected by chemotherapy and radiotherapy.

They also found that radiotherapy can cause mouth dryness and dental problems. Patients who underwent surgery or radiotherapy alone have noted problems with chewing and taste, according to the study.

Researchers found that transoral robotic surgery were able to better preserve HRQOL, and deliver the same beneficial results. Researchers said that not every patient will be a candidate for that surgery. However, alternative or novel treatments could likely impact patient’s quality-of-life, the study concluded.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com